Ovation.io and PrecisionLife team to develop drug-response biomarkers for GLP-1 therapies
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Jaypirca is making waves in the fight against B-cell malignancies
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The company will soon be launching a new portfolio of products in this segment
Subscribe To Our Newsletter & Stay Updated